US-based advanced wound care company looking to sell its Out-of-US (OUS) rights to an international strategic partner for commercial and manufacturing rights.
The product is a negative pressure wound therapy, developed for tier 2/3 cities in India and South Asia with collaboration from local surgeons.
FDA 510k application in place for market clearance has completed a 14 patient clinical trial with peer-reviewed data.
NPWT is a clinically established standard of care to treat patients with chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), skin flaps and grafts. Its integrated wound management system is designed for use in acute, extended and home care settings.